Patient preferences about organ offers in liver transplantation
Michael L. Volk – 20 October 2014
Cyclic adenosine monophosphate–responsive element modulator alpha overexpression impairs function of hepatic myeloid‐derived suppressor cells and aggravates immune‐mediated hepatitis in mice
Linda Hammerich, Klaudia Theresa Warzecha, Martina Stefkova, Matthias Bartneck, Kim Ohl, Nikolaus Gassler, Tom Luedde, Christian Trautwein, Klaus Tenbrock, Frank Tacke – 20 October 2014 – Molecular factors driving immune‐mediated inflammation in the liver are incompletely understood. The transcription factor, cyclic adenosine monophosphate‐responsive element modulator alpha (CREMα) can endorse differentiation of T lymphocytes toward T‐helper (Th)17 cells, thereby promoting autoimmunity in systemic lupus erythematosus or lung inflammation.
Development and validation of a “capture‐fusion” model to study drug sensitivity of patient‐derived hepatitis C
Morven E. Cunningham, Alia Javaid, Jenny Waters, Joseph Davidson‐Wright, Joshua L.C. Wong, Meleri Jones, Graham R. Foster – 20 October 2014 – Emerging therapies for chronic hepatitis C viral (HCV) infection involve inhibition of viral enzymes with drug combinations. Natural, or treatment‐induced, enzyme polymorphisms reduce efficacy. We developed a phenotyping assay to aid drug selection based on viral transfer from monocytes to hepatocytes.
Glycemic responses to intermittent hepatic inflow occlusion in living liver donors
Sangbin Han, Justin Sangwook Ko, Sang‐Man Jin, Jong Man Kim, Soo Joo Choi, Jae‐Won Joh, Yang Hoon Chung, Suk‐Koo Lee, Mi Sook Gwak, Gaabsoo Kim – 20 October 2014 – The occurrence of glycemic disturbances has been described for patients undergoing intermittent hepatic inflow occlusion (IHIO) for tumor removal. However, the glycemic responses to IHIO in living liver donors are unknown. This study investigated the glycemic response to IHIO in these patients and examined the association between this procedure and the occurrence of hyperglycemia (blood glucose > 180 mg/dL).
Reuse of a transplanted liver graft: First experience in South America
Domingo Balderramo, María Eugenia Romero, Álvaro Alcaraz, Martín Barrabino, Martín Maraschio – 20 October 2014
Sofosbuvir, simeprevir, and ribavirin for the treatment of hepatitis C virus recurrence in human immunodeficiency virus/hepatitis C virus–coinfected liver transplant recipients
Isabel Campos‐Varela, Stephanie Straley, Eliana Z. Agudelo, Laurie Carlson, Norah A. Terrault – 20 October 2014
Serotonin in liver tumor: Friend or foe?
Qing Pang, Chang Liu, Jing‐Yao Zhang, Kai Qu, Si‐Dong Song, Su‐Shun Liu, Xin‐Sen Xu – 20 October 2014
Reply
Andrea Lisotti, Francesco Azzaroli, Giuseppe Mazzella – 20 October 2014
Sofosbuvir with peginterferon‐ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis
Eric Lawitz, Fred Poordad, Diana M. Brainard, Robert H. Hyland, Di An, Hadas Dvory‐Sobol, William T. Symonds, John G. McHutchison, Fernando E. Membreno – 16 October 2014 – Sofosbuvir (SOF) in combination with ribavirin (RBV) for 12 or 24 weeks is the current standard of care for patients infected with hepatitis C virus (HCV) genotypes 2 and 3, respectively. However, in clinical trials treatment‐experienced patients, particularly those with cirrhosis, had suboptimal sustained virological response (SVR) rates.
Sofosbuvir with peginterferon‐ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis
Eric Lawitz, Fred Poordad, Diana M. Brainard, Robert H. Hyland, Di An, Hadas Dvory‐Sobol, William T. Symonds, John G. McHutchison, Fernando E. Membreno – 16 October 2014 – Sofosbuvir (SOF) in combination with ribavirin (RBV) for 12 or 24 weeks is the current standard of care for patients infected with hepatitis C virus (HCV) genotypes 2 and 3, respectively. However, in clinical trials treatment‐experienced patients, particularly those with cirrhosis, had suboptimal sustained virological response (SVR) rates.